The prevalence of hepatitis C virus (HCV) infection in hematopoietic stem cell transplantation (HSCT) recipients has been estimated to be approximately 6%. 1 Studies have consistently demonstrated that HCV infection increases the risk for early non-relapse mortality after HSCT. [2] [3] [4] HCV-infected HSCT recipients are more likely to develop sinusoidal obstruction syndrome (SOS), graft-versus-host disease (GvHD), hepatic inflammation and fatal liver failure compared with non-HCV-infected HSCT recipients. Long term, there is also an increased risk for developing cirrhosis and hepatocellular carcinoma at an accelerated rate. 1, 5, 6 The standard therapy for HCV infections has been pegylated IFN-α and ribavirin. 7 IFN-α and ribavirin therapy is poorly tolerated and the efficacy is suboptimal with only~50% of HSCT patients achieving a sustained viral response. 8 In 2013, the Food and Drug Administration approved two direct acting antivirals (DAAs), simeprevir and sofosbuvir, for treatment of HCV. Simeprevir is an NS3/4A protease inhibitor and sofosbuvir is a nucleotideanalog NS5B polymerase inhibitor. The once daily oral DAAs have been reported to be well tolerated. 9 Combined, 92% of HCVinfected non-HSCT adults attained a sustained viral response in a randomized trial. 9 DAAs have the potential to significantly change the natural course of HCV infection in HSCT recipients. 10 Although new guidelines for the diagnosis and management of HCV infection in HSCT recipients are becoming available, information regarding DAAs in pediatric patients undergoing HSCT remains sparse. 7, 10 We present a case of an HCV-infected pediatric patient who was treated with simeprevir and sofosbuvir immediately following an umbilical cord blood transplantation.
A 4-year-old girl with B-cell acute lymphoblastic leukemia who was initially treated in Nicaragua was referred to our institution upon relapse. She had no prior history of HCV testing or infection and initial serologic evaluation for HCV antibody was negative. Other viral serologic testing was positive for Epstein-Barr viral capsid antigen, CMV and HSV type 1/2 IgG. Hepatitis B surface and core antibody was positive but tests for surface antigen and DNA were negative. HIV antibody screen was nonreactive. After poor response to chemotherapy, she was referred for an allogeneic HSCT. During her pre-HSCT evaluation, nucleic acid testing detected HCV RNA. Confirmation testing was positive and quantitative PCR for HCV RNA was significantly elevated at log 7.28 (312 00 000 IU/mL) ( Figure 1a 2 ) was modified to reduce the fractionated total body irradiation (TBI) (12.0 Gy) and cyclophosphamide (100 mg/kg) dose. GvHD prophylaxis included cyclosporine and mycophenolate mofetil. Since mycophenolate mofetil can lead to fatal fibrosing cholestatic hepatitis, the dosing was decreased from three times daily to twice daily. Neutrophil engraftment occurred on day +13 after HSCT and peripheral blood chimerism by variable number tandem repeat was 100% donor. The patient developed sinusoidal obstruction syndrome on day +20 after HSCT with elevated bilirubin of 4.1 mg/dL, weight gain 45%, right upper quadrant tenderness and hepatomegaly. Ultrasound demonstrated enlarged liver (13.7 cm) with normal hepatopetal flow. Defibrotide was given until day +28 when sinusoidal obstruction syndrome resolved. She recovered from her regimen-related toxicities and was discharged on day +36 after HSCT. There was no evidence of GvHD and mycophenolate mofetil was discontinued on day +50 after HSCT.
Clearance of HCV infection can occur without a humoral immune response but requires a strong HCV-specific T-cell response directed against specific viral epitopes. 11, 12 We confirmed detection of HCV-specific donor CD3 + T cells after HSCT using donor-restricted HLA-A*03:01 tetrameter for an HCV epitope, KLVALGINAV. Furthermore, numerical recovery of lymphocytes was monitored monthly (Figure 1c) . With immune recovery, the patient developed symptoms of acute hepatitis including fever, nausea, vomiting, abdominal pain, jaundice and elevated liver function test. HCV treatment with daily sofosbuvir (200 mg) and simeprevir (75 mg) was initiated on day +88, 2 weeks prior to the planned start date of day +100 after HSCT. HCV RNA titers declined~2 log per week and was undetectable after 33 days of treatment (Figure 1 ). Despite negative HCV PCR, the patient continued with extrahepatic manifestation of HCV. The total WBC increased to 31.9 × 10 3 /mm 3 with 12% lymphocytes. Immunophenotype demonstrated CD19 + CD20 − B cells that were polytypic for kappa and lambda light chains (kappa to lambda ratio of 10:17) and the CD19 + CD20 dim+ B cells were kappa light chain restricted (kappa to lambda ratio of 18:1). Ig heavy chain gene rearrangements showed polyclonal gene rearrangement patterns for the IgH locus. IgG was elevated (2585 mg/dL) and immunofixation studies detected kappa IgM and lambda IgG monoclonal proteins. Cryoglobulins remained negative although she developed warm antibody autoimmune hemolytic anemia with polyspecific direct anti-IgG on day 128. Her autoimmune hemolytic anemia was refractory to aggressive treatment including IVIG, steroids, rituximab and bortezomib. The patient underwent a splenectomy on day 186 and the hemolysis resolved within 1 week postoperatively.
The patient was treated with a total of 24 weeks with sofosbuvir and simeprevir and viral load was monitored for 24 weeks after completing HCV treatment She completed HCV therapy (day +250), she was off all immunosuppression with no evidence of GvHD. Liver enzymes returned to normal values. Ultrasound showed no hepatomegaly with normal echogenicity. Repeat biopsy 1 year after HSCT showed marked hemosiderosis, decreased number of lymphocytes and inflammation but no evidence of fibrosis or cirrhosis (Figures 2d and f) . Serologic testing for HCV antibodies remained negative throughout. The patient is now 41½ year after HSCT and remains HCV negative in clinical remission.
HCV treatment using DAAs in HSCT recipients may decrease the risk for early non-relapse mortality and alleviate the associated long-term risks in survivors, particularly in younger children. However, current recommendations for HCV treatment for HSCT recipients are based on clinical trials involving other patient populations. 7, 10 As more data regarding HCV treatment are reported, optimal recommendations for HSCT recipients will likely develop. The HCV guidance from the American Association for the Study of Liver Disease and Infectious Disease Society of America recommend choosing the appropriate drug combination based on host and viral factors. 7, 13 Treatment recommendations are based on HCV genotype and host factors such as the level of cirrhosis, co-infections and co-morbidities.
14 For HSCT recipients, drug metabolism, renal function and drug interactions will likely impact HCV treatment. Simeprevir and sofosbuvir are metabolized by the CYP3A4 isoform of the CYP450 enzymes and drug metabolism can be influenced by host variance in CYP3A4 genotype. The patient's CYP3A4 and CYP3A5 genotype (*1/*1 and *1A/*1A, respectively) was wild type with normal phenotype suggesting normal drug metabolism. Furthermore, drug levels (cyclosporine) should be monitored closely since protease inhibitors (simeprevir) may increase chemotherapy or immunosuppressive agents while the polymerase inhibitors (sofosbuvir) are affected by immunosuppressive agents such as cyclosporine, tacrolimus and sirolimus. 10 Data regarding the use of DAAs in treatment of pediatric HSCT recipients infected with HCV are very limited. We report that simeprevir and sofosbuvir were well tolerated and led to a sustained viral response in a pediatric patient undergoing umbilical cord blood transplantation. Despite viral clearance, the donor immune system can produce extrahepatic manifestations of HCV and thus clearance prior to HSCT may have additional benefits. In summary, the highly effective and well-tolerated oral DAAs can lead to a sustained viral response and will likely impact the treatment for HCV before and after HSCT. 
